ClinicalTrials.gg
TerminatedNCT01237340Updated Aug 7, 2013Results posted

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study

A Phase 3 interventional study of Saizen® in Growth Hormone Deficiency (GHD), sponsored by EMD Serono. Terminated at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-08-07.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment

Why this study was terminated
The Sponsor voluntarily terminated this trial because compliance to strict Good Clinical Practice (GCP) requirements was not ensured - No safety concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
33rd of 60
59 · median 66
Started
2010
with 3 others
Phase 3
23 of 60
2 open now
Registered
37th of 60
by date
Lead sponsor
3 of 60
EMD Serono

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 33rd largest by enrollment, is one of 4 that started in 2010, is one of 23 in phase 3, and was the 37th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

To assess the immunogenicity of Saizen® solution for injection in adult subjects with documented Growth Hormone Deficiency (GHD).

03

Conditions studied

  • Growth Hormone Deficiency (GHD)

Browse trials for

Keywords

  • Adult Growth Hormone Deficiency (AGHD)
  • immunogenicity
  • growth hormone
  • antibodies
  • GH biomarkers
  • IGF-I
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male and female subjects, 18-60 years of age, inclusive, at the time the is signed
  • Subjects who have confirmed adult GHD
  • Subjects who are growth hormone (GH) treatment-naive or had received Saizen® (freeze-dried formulation) for pediatric GHD (PGHD), or are currently receiving Saizen® freeze-dried formulation for adult GHD (AGHD)
  • Subjects who have binding antibody-negative (BAbs-) at screening
  • Subjects who have no evidence of concomitant disease, intercurrent illness, or resultant therapy that would interfere with subject compliance, the evaluation of study results, or compromise the safety of the subject
  • Female subjects of who have a negative serum pregnancy test at the screening visit (and at each scheduled visit during the study)
  • Subjects who are willing to comply with the procedures of the study
  • Subjects who are willing to sign an Independent Ethics Committee/Institutional Review Board approved informed consent form
  • Other protocol-defined inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Subjects who are currently receiving or have previously received treatment for adult GHD or any other indication, including PGHD, with a commercial GH product other than Saizen® freeze-dried formulation
  • Subjects who had a chronic underlying disease within 6 months prior to screening or concomitant medication(s) that in the opinion of the investigator would exclude the subject from the trial
  • Subjects who have significant renal impairment
  • Subjects who have diabetes mellitus
  • Subjects who are
  • Subjects who have a current or a history of any malignancy (excluding fully-treated basal cell carcinoma)
  • Subjects who have participated in another study and received an drug within 30 days prior to screening visit
  • Subjects who have abnormal laboratory value(s)
  • Subjects who have known or allergy to exogenous human GH or any of the or phenol, the bacteriostatic agent in the Saizen® solution for injection
  • Other protocol-defined exclusion criteria may apply
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Saizen®

    Drug: Saizen®

Interventions

  • Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.

    Also known as: r-hGH, Somatropin

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Developed Positive Binding Antibodies (BAbs+) to Saizen®

    Binding antibodies (BAbs) are all antibodies which are capable of binding to the investigational drug molecule (Saizen®), irrespective of their binding site.

    Time frame: Baseline up to Week 26

Secondary outcomes

  1. Number of Participants Who Developed Positive Neutralizing Antibodies (NAbs+) to Saizen®

    Neutralizing antibodies (NAbs) are defined as a subgroup of BAbs which bind to the active sites of the investigational drug molecule (Saizen®) and therefore neutralize its potency.

    Time frame: Baseline up to Week 26

  2. Insulin-like Growth Factor-I (IGF-1) Levels

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 13, Week 18, Week 26

  3. Insulin-like Growth Factor-I Standard Deviation Score (IGF-1 SDS)

    Insulin-like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) was provided by the central laboratory; its calculation is based on the actual value of IGF-1 minus mean reference value of IGF-1 divided by reference standard deviation of IGF-1.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 13, Week 18, Week 26

  4. Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 13, Week 18, Week 26

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Adverse events (AEs): Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs occurring after the first administration of Saizen® solution for injection (on Day 1) up to the scheduled routine post treatment follow-up visit (4 weeks \[28 days\] after the final administration of Saizen® solution for injection).

    Time frame: Day 1 up to 28 days after last dose of study treatment

07

Results

Posted Oct 11, 2012

Participant flow

Participant flow — Overall Study
MilestoneSaizen®
Started59
Completed19
Not completed40
Withdrew: Adverse event3
Withdrew: Withdrawal by subject1
Withdrew: Early termination of the trial36

Outcome measures

PrimaryNumber of Participants Who Developed Positive Binding Antibodies (BAbs+) to Saizen®

Binding antibodies (BAbs) are all antibodies which are capable of binding to the investigational drug molecule (Saizen®), irrespective of their binding site.

Time frame:
Baseline up to Week 26
Reported as:
Number · participants
Number of Participants Who Developed Positive Binding Antibodies (BAbs+) to Saizen®
participantsSaizen®
Number of Participants Who Developed Positive Binding Antibodies (BAbs+) to Saizen®1
SecondaryNumber of Participants Who Developed Positive Neutralizing Antibodies (NAbs+) to Saizen®

Neutralizing antibodies (NAbs) are defined as a subgroup of BAbs which bind to the active sites of the investigational drug molecule (Saizen®) and therefore neutralize its potency.

Time frame:
Baseline up to Week 26
Reported as:
Number · participants
Number of Participants Who Developed Positive Neutralizing Antibodies (NAbs+) to Saizen®
participantsSaizen®
Number of Participants Who Developed Positive Neutralizing Antibodies (NAbs+) to Saizen®0
SecondaryInsulin-like Growth Factor-I (IGF-1) Levels
Time frame:
Baseline, Week 2, Week 4, Week 8, Week 13, Week 18, Week 26
Reported as:
Mean · nanomole per liter (nmol/L)
Insulin-like Growth Factor-I (IGF-1) Levels
nanomole per liter (nmol/L)GH Treatment-NaiveGH Treatment-Experienced
Baseline (n = 49, 8)11.492 ± 6.69420.225 ± 10.194
Week 2 (n = 47, 8)18.923 ± 10.39428.663 ± 9.001
Week 4 (n = 49, 8)19.914 ± 11.53224.500 ± 11.176
Week 8 (n = 49, 8)21.155 ± 10.52027.075 ± 6.815
Week 13 (n = 46, 8)23.415 ± 8.02026.413 ± 8.767
Week 18 (n = 31, 4)24.948 ± 9.30025.650 ± 8.502
Week 26 (n = 48, 8)24.117 ± 11.08527.438 ± 12.402
SecondaryInsulin-like Growth Factor-I Standard Deviation Score (IGF-1 SDS)

Insulin-like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) was provided by the central laboratory; its calculation is based on the actual value of IGF-1 minus mean reference value of IGF-1 divided by reference standard deviation of IGF-1.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 13, Week 18, Week 26
Reported as:
Mean · standard deviation score
Insulin-like Growth Factor-I Standard Deviation Score (IGF-1 SDS)
standard deviation scoreGH Treatment-NaiveGH Treatment-Experienced
Baseline (n = 49, 8)-2.914 ± 2.268-0.550 ± 2.274
Week 2 (n = 47, 8)-0.926 ± 2.3000.951 ± 1.411
Week 4 (n = 49, 8)-0.867 ± 2.6150.153 ± 1.762
Week 8 (n = 49, 8)-0.464 ± 2.2740.834 ± 1.063
Week 13 (n = 46, 8)0.212 ± 1.8320.666 ± 1.225
Week 18 (n = 31, 4)0.455 ± 1.8161.043 ± 1.144
Week 26 (n = 48, 8)0.167 ± 2.0160.544 ± 1.894
SecondaryInsulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels
Time frame:
Baseline, Week 2, Week 4, Week 8, Week 13, Week 18, Week 26
Reported as:
Mean · nmol/L
Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels
nmol/LGH Treatment-NaiveGH Treatment-Experienced
Baseline (n = 51, 8)124.941 ± 31.899133.375 ± 36.024
Week 2 (n = 49, 8)137.408 ± 35.088162.125 ± 35.203
Week 4 (n = 49, 8)144.592 ± 32.632147.750 ± 26.451
Week 8 (n = 50, 8)147.460 ± 36.381156.625 ± 36.190
Week 13 (n = 47, 8)149.404 ± 28.272151.875 ± 35.679
Week 18 (n = 32, 4)148.813 ± 39.754155.500 ± 36.235
Week 26 (n = 49, 8)152.429 ± 35.649147.500 ± 30.402
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

Adverse events (AEs): Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs occurring after the first administration of Saizen® solution for injection (on Day 1) up to the scheduled routine post treatment follow-up visit (4 weeks \[28 days\] after the final administration of Saizen® solution for injection).

Time frame:
Day 1 up to 28 days after last dose of study treatment
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
participantsSaizen®
Number of Participants With Treatment Emergent Adverse Events (TEAEs)40

Adverse events

Collected over Day 1 up to 28 days after last dose of study treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Saizen®—3/59 (5.1%)13/59 (22%)
Most frequent serious events
Most frequent serious events
EventSaizen®
AnxietyPsychiatric disorders1/59
DepressionPsychiatric disorders1/59
Hepatic enzyme increasedInvestigations1/59
HyponatraemiaMetabolism and nutrition disorders1/59
Most frequent other events
Most frequent other events
EventSaizen®
Oedema peripheralGeneral disorders5/59
NasopharyngitisInfections and infestations4/59
HeadacheNervous system disorders3/59
Insulin-like growth factor increasedInvestigations3/59
CoughRespiratory, thoracic and mediastinal disorders3/59

Baseline characteristics

Age Continuous
Age Continuous(years)Saizen®
Mean44.7 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Saizen®
Female30
Male29
08

Study locations

1 site
  • US Medical Information, Massachusetts, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2010
First posted
Nov 9, 2010
Start
Oct 2010
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results first posted
Oct 11, 2012
Last update
Aug 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01237340
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Nov 9, 2010
Start date
Oct 2010
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Oct 11, 2012
Last update
Aug 7, 2013

Study contacts

Medical Responsible
study director · Merck Serono S.A., Geneva

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion